Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2026
Liver stiffness in AL amyloidosis: interest in diagnosis and prognosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Carrier Paul, Loustaud-Ratti Véronique, Cadranel Jean-François, Rigaud Céline, Randrianarivo Bienvenue, Lavergne David, Alric Laurent, Baron Aurore, Nguyen Khac Eric, Pauwels Arnaud, Bettan Louis, Causse Xavier, Zougmoure Honoré, El Kharrazi Abdelali, Debette-Gratien Marilyne, Cypierre Anne, Roussel Murielle, Jaccard Arnaud
Аннотация
INTRODUCTION: Liver is frequently involved in AL amyloidosis. Diagnosis usually relies on hepatomegaly and elevated alkaline phosphatase levels. Liver stiffness (LS) at diagnosis and, overall, its follow-up remains to be further explored.
MATERIAL AND METHODS: We assessed LS at diagnosis in a retrospective multicenter cohort. Patients were classified as having liver involvement only (group 1), heart involvement only (group 2), both (group 3), or neither (group 4). In a prospective monocentric cohort, we evaluated changes in LS over time.
RESULTS: In the retrospective cohort of 56 patients, median LS values were 75 kPa in group 1 (n = 14), 11.6 kPa in group 2 (n = 17), 28.8 kPa in group 3 (n = 13), and 6.4 kPa in group 4 (n = 12). The ROC curve in patients with liver involvement identified an optimal cutoff of 13.6 kPa, with 92% sensitivity and 71% specificity. In the prospective cohort of 19 treated patients, median LS decreased with 91% reduction, 26% reduction, 79% reduction and 19% reduction respectively in groups 1, 2, 3 and 4.
CONCLUSION: LS is useful for diagnosing hepatic involvement in amyloidosis. A threshold of 13.6 kPa, in the absence of other etiologies, could be prosposed as diagnostic criteria. A decrease in LS greater than 50% can be a marker of hepatic recovery. Clinically and prognostically significant cutoffs still need to be confirmed in future, larger-scale studies.
MATERIAL AND METHODS: We assessed LS at diagnosis in a retrospective multicenter cohort. Patients were classified as having liver involvement only (group 1), heart involvement only (group 2), both (group 3), or neither (group 4). In a prospective monocentric cohort, we evaluated changes in LS over time.
RESULTS: In the retrospective cohort of 56 patients, median LS values were 75 kPa in group 1 (n = 14), 11.6 kPa in group 2 (n = 17), 28.8 kPa in group 3 (n = 13), and 6.4 kPa in group 4 (n = 12). The ROC curve in patients with liver involvement identified an optimal cutoff of 13.6 kPa, with 92% sensitivity and 71% specificity. In the prospective cohort of 19 treated patients, median LS decreased with 91% reduction, 26% reduction, 79% reduction and 19% reduction respectively in groups 1, 2, 3 and 4.
CONCLUSION: LS is useful for diagnosing hepatic involvement in amyloidosis. A threshold of 13.6 kPa, in the absence of other etiologies, could be prosposed as diagnostic criteria. A decrease in LS greater than 50% can be a marker of hepatic recovery. Clinically and prognostically significant cutoffs still need to be confirmed in future, larger-scale studies.